Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

8/4/2023: MIRA Pharmaceuticals, (MIRA) INTERVIEWED BY THE WALL STREET RESOURCE

Go there now

Company News

As of June 23, 2025 • 12:11 PM ET

Date/Time Source News Release
06/18/2025 08:30 AM EDT ACCESS Newswire MIRA Pharmaceuticals' Lead Drug Candidate Ketamir-2 First Manuscript Accepted for Publication in the Peer-Reviewed Journal Frontiers in Pharmacology
05/28/2025 08:30 AM EDT ACCESS Newswire MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program
05/08/2025 08:00 AM EDT ACCESS Newswire MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review
05/06/2025 08:00 AM EDT ACCESS Newswire MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity
04/23/2025 08:00 AM EDT ACCESS Newswire MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation
04/16/2025 08:00 AM EDT ACCESS Newswire MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion
04/01/2025 08:00 AM EDT ACCESS Newswire MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain
03/24/2025 07:30 AM EDT ACCESS Newswire MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development
03/13/2025 08:00 AM EDT ACCESS Newswire MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain
03/04/2025 08:00 AM EST ACCESS Newswire MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain
Page

Additional News

As of June 23, 2025 • 12:11 PM ET

Date/Time Source News Release
05/12/2025 07:00 AM EDT US Earnings Reports Expected US Company Earnings on Monday, May 12th, 2025
05/12/2025 05:30 AM EDT US Earnings Reports Expected earnings - MIRA Pharmaceuticals Inc.
05/08/2025 09:30 AM EDT SeekingAlpha MIRA Pharmaceuticals board approves SKNY Pharmaceuticals acquisition; combined value tops $60M
04/23/2025 10:29 AM EDT SeekingAlpha MIRA Pharmaceuticals reports positive in vitro drug release data for topical Ketamir-2
04/16/2025 12:30 PM EDT AllPennyStocks.com Pharmaceutical Stock Jumps After Key Trial Findings
04/16/2025 09:44 AM EDT 24/7 Market News Mobile Gaming Industry Report Supports Siyata Mobile Merger Target, Core Gaming, Meteoric Rise
04/06/2025 06:49 PM EDT KlickAnalytics MIRA - Historical Price Movements Surrounding Earnings
04/06/2025 06:44 PM EDT KlickAnalytics MIRA - Historical Earnings Price Analysis
03/24/2025 07:53 AM EDT SeekingAlpha MIRA Pharmaceuticals signs LOI to acquire SKNY Pharmaceuticals
11/27/2024 04:31 AM EST US Earnings Reports Expected earnings - MIRA Pharmaceuticals Inc.
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.